10 results about "Synthetic DNA" patented technology

The present invention relates to a method of selecting a polypeptide for display on a genetic display system according to activity, comprising the steps of: displaying the polypeptide on the genetic display system, screening a system for binding to a target, and selecting a member binding to the target; cloning a nucleic acid encoding the polypeptide from a member of the display system, and expressing the nucleic acid in an expression system to produce the polypeptide, or sequencing the polypeptide from a member of the display system, and cloning and expressing the polypeptide or a library of polypeptides using synthesis-based DNA; and determining the activity of the polypeptide in an assay.

The disclosure provides for methods of constructing synthetic chromosomes including the steps of providing host cells with an endogenous chromosome, transforming a cloning vector and a cloning cassette into the host cells, excising target genomic nucleic acids from the endogenous chromosome, recombining the excised target genomic nucleic acids with the cloning cassette via homologous recombination to form heterologous vectors comprising cloned sequences, extracting the heterologous vectors containing the cloned sequences from the host cells, digesting the heterologous vectors with a restriction endonuclease to release the cloned sequences from the heterologous vectors to provide released cloned sequences, and introducing the released cloned sequences, a centromere cassette, and a yeast artificial chromosomes or bacterial artificial chromosomes into a second host cell, such that the released cloned sequences, the centromere cassette, and the YAC or BAC recombine with one another via homologous recombination to produce the synthetic chromosome.

Embodiments disclosed herein provide methods of using synthetic DNA spike-ins (SDSIs) to detect, prevent, and quantify contamination in amplicon sequencing. These embodiments may, but are not limited to, reveal sample swaps, intra-batch contamination, and, on a larger scale, intra-laboratory contamination. Embodiments disclosed herein also provide synthetic DNA spike-ins for use in amplicon-based sequencing methods.

The present invention relates to a synthetic DNA construct comprising (A) a nucleic acid encoding transfer RNA and (B) a 5' leader sequence, wherein the 5' leader sequence contains a sequence motif for controlling the expression level of the transfer RNA.

The application discloses an aquifer delineation method and device based on synthetic DNA-thermal double tracing, and relates to the technical field of hydrogeophysical tracer tomography imaging, and the method comprises the following steps: obtaining DNA tracer travel time data and thermal tracer travel time data collected at an observation well after simultaneously injecting different types of synthetic DNA tracers and thermal tracers at multiple depths of an injection well of a target aquifer system; according to the DNA tracer travel time data and the thermal tracer travel time data, applying a SIRT inversion method based on a double-tracer mechanism to inversely calculate the permeability coefficient of the target aquifer, and further obtaining a water diffusion coefficient, a water storage rate and thermal characteristic parameters. The permeability coefficient of the target aquifer is inversely calculated through the double-tracer mechanism, and the aquifer heterogeneity can be accurately delineated.

A synthetic DNA molecule comprising one segment encoding a tumor neoantigen or an epitope from an infectious agent under the control of a promoter for the transcription into a corresponding RNA molecule and a segment for the translation of the translated RNA molecule into a peptide.

Disclosed herein are mutants of bacteriophage Phi29 DNA polymerase with improved primer recognition, compared to the wild-type enzyme. Certain mutants comprise one or both of the mutations K64R or M97K. The provided mutants are capable of using more efficiently shorter and longer random synthetic DNA primers than wild-type Phi29 DNA polymerase, generating more amplification product in Multiple Displacement Amplification (MDA) reactions. The inventive mutants amplify human genomic DNA with less bias and better coverage in comparison to reactions carried out with wild-type Phi29 DNA polymerase.

Compositions and methods are provided for forming a single RNA polynucleotide from a plurality of DNA oligonucleotides in a single reaction chamber using combined reagents in a single step reaction. DNA polymerase, RNA polymerase and single stranded (ss) DNA oligonucleotides are combined where each DNA oligonucleotide has one or more sequence modules, wherein one sequence module in the first ss DNA oligonucleotide is complementary to a sequence module at the 3′ end of the second ss DNA oligonucleotide; and wherein a second module on the first ss DNA oligonucleotide is an RNA polymerase promoter sequence; and forming a single RNA polynucleotide, excluding the RNA promoter sequence, derived from the first and second DNA oligonucleotides.

Embodiments of the present invention generally relate to devices and methods related to deoxyribonucleic acid (DNA) synthesis. A device for synthesizing DNA is provided. The device includes a LED panel, the LED panel includes a backplane, the backplane having a backplane surface, the backplane surface having at least one contact pad disposed over the backplane surface, a plurality of LED, the plurality of LEDs disposed over the backplane surface, where each LED of the plurality of LEDs couples to a contact pad, pixel isolation (PI) structures, the PI structures disposed over the backplane surface and between the plurality of LEDs, the PI structures defining a plurality of wells, and a coating disposed over the LED panel, the coating operable to seal each well to hold a liquid.

The application discloses a biosensor for detecting AKI based on urine-synthesized DNA and application thereof, and belongs to the field of biomedical technology. The biosensor is constructed by loading bio-orthogonal DNA on molybdenum-doped tungsten oxide nanosheets which are responsive to ROS degradation. The biosensor is combined with blank liposomes to detect acute kidney injury (AKI), and the reticuloendothelial system is inhibited by the blank liposomes, so that the biosensor can enter the kidney metabolic pathway more. In the high ROS environment of AKI, the biosensor structure is destroyed, bio-orthogonal DNA is released, and finally excreted through urine. By enriching bio-orthogonal DNA in urine, early diagnosis of AKI is finally realized. The application can solve the sensitivity and specificity problems in AKI detection, and provide a new technology for early screening of AKI in resource-poor areas or countries.